Project Grant DP2AI201017
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $467K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $427,623 to The Washington University on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research dissecting how HIV-induced immunometabolic perturbation impairs tuberculosis control in people living with HIV despite effective antiretroviral therapy and viral suppression. The research...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $305,908 on December 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of sigma-factor-dependent transcriptional control in Mycobacterium tuberculosis. The research employs experimental and computational approaches to understand the role of an intrinsically disordered region (IDR) in the sigma-A factor, which directs RNA polymerase to genes across...
- The National Institute of Allergy and Infectious Diseases awarded Saint Louis University $259,125 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to dissect the contribution of neutrophils to diabetes and tuberculosis comorbidity. The research investigates how altered neutrophil function in diabetic patients increases susceptibility to active tuberculosis disease and worsens outcomes. The project examines neutrophilic inflammation as a central feature...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $233,250 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model toll-like receptor 8 gain-of-function disease mechanisms and identify potential therapeutic targets. The project investigates a newly identified inborn error of immunity caused by genetic variants in TLR8, an X-linked endosomal receptor expressed in myeloid cells. The disease presents with...
- The National Heart, Lung, and Blood Institute awarded The Washington University $680,379 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of sphingolipid biosynthesis during lung infection, specifically examining how SPTLC2, an essential enzyme subunit in sphingolipid synthesis, affects survival during Mycobacterium tuberculosis infection in CD11C+ lung macrophages and dendritic cells. The project addresses immune response mechanisms...
- The National Institute of Allergy and Infectious Diseases awarded Saint Louis University $192,500 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular mechanisms by which a monocyte chemoattractant protein-1 (MCP-1) promoter polymorphism confers susceptibility to pulmonary tuberculosis infection. The research addresses why approximately 10% of individuals infected with Mycobacterium tuberculosis progress to active pulmonary...
- The National Institute of Allergy and Infectious Diseases awarded University of Massachusetts Medical School $139,968 on September 30, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the relationship between genetic variants, transcriptional responses, and Mycobacterium tuberculosis infection outcomes in macrophages derived from genetically diverse Collaborative Cross mice. The research explores how polymorphisms such as those in the STAT2 locus...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $664,076 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R01AI196089) to investigate the molecular mechanisms by which Staphylococcus aureus alpha-toxin impairs antigen-specific T cell response and adaptive immunity. The research examines how S. aureus alpha-toxin (HLA) functions as a virulence factor and potential vaccine target. The work...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $638,220 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate DNA ADP-ribosylation in bacterial-phage immune conflicts. The research examines how DNA ADP-ribosylation, a chemical modification that blocks DNA replication and serves as a bacterial anti-phage defense mechanism, operates across bacterial toxin-antitoxin systems and phage counter-mechanisms....
- The National Institute of Allergy and Infectious Diseases awarded the University of Missouri System $2.767 million on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the NFKB signaling network in the regulation of resident T cell memory. The research addresses how tissue-resident memory T cells (TRM) are generated and maintained in the lungs following infection. While CD8 TRM cells in multiple tissues provide superior protection against...